Influence of proton pump inhibitors andVKORC1mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study

Use of proton pump inhibitors and the risk of coronary events in new users of low-dose acetylsalicylic acid in UK primary care

(2013) L. A. García Rodríguez et al.   THROMBOSIS AND HAEMOSTASIS

Use of clopidogrel and proton pump inhibitors after a serious acute coronary event: Risk of coronary events and peptic ulcer bleeding

(2013) Luis Rodríguez et al.   THROMBOSIS AND HAEMOSTASIS

The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel

(2011) B. W. Ogilvie et al.   DRUG METABOLISM AND DISPOSITION

Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data

(2011) Rianne M.F. van Schie et al.   EUROPEAN HEART JOURNAL

Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs

(2011) Ana Estany-Gestal et al.   Pharmacogenetics and Genomics

Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel

(2011) Wiktor Kuliczkowski et al.   THROMBOSIS AND HAEMOSTASIS

Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests

(2011) Thomas Gremmel et al.   THROMBOSIS RESEARCH

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters

(2010) Christof Geisen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements

(2010) Kendra A Ross et al.   JOURNAL OF HUMAN GENETICS

Exploration of the binding of proton pump inhibitors to human P450 2C9 based on docking and molecular dynamics simulation

(2010) Rongwei Shi et al.   JOURNAL OF MOLECULAR MODELING

Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis

(2010) J. M. SILLER-MATULA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes

(2010) Martina Teichert et al.   Pharmacogenetics and Genomics

Pharmacogenetics of coumarinic oral anticoagulants

(2010) Vangelis G Manolopoulos et al.   PHARMACOGENOMICS

Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1 , F7 , GGCX , CALU , EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy

(2010) B. Luxembourg et al.   THROMBOSIS AND HAEMOSTASIS

Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation

(2010) Rudolf Jarai et al.   THROMBOSIS AND HAEMOSTASIS

Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements

(2009) Janne Cadamuro et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

(2008) BF Gage et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS